Shots:

• Ivantis to receive $475M up front along with additional payments upon achievement of regulatory & commercial milestones. The transaction is expected to close in Q1’22
• The acquisition expands Alcon’s surgical portfolio & uses the commercial execution expertise across cataract, refractive, retina & glaucoma. Hydrus Microstent is approved for use in conjunction with cataract surgery in the US & for standalone use or in conjunction with cataract surgery in the UK, Canada, Australia, Singapore & Germany
• The HORIZON study of Hydrus Microstent showed 65% remained medication-free @5yrs. post-implant, 60% reduction in risk of invasive secondary glaucoma surgeries over cataract surgery alone

 Ref: Alcon | Image: Alcon